Gamma-delta T cell therapy for glioblastoma
Part of Cancer clinical trials.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have glioblastoma (a type of brain tumor) that has continued to grow or returned after previous treatments
- You are able to do daily activities with some help (Karnofsky score 60% or more)
- You finished your last cancer treatment (like radiation or chemotherapy) at least 4 weeks ago, and side effects from that treatment are mostly gone
- You can have an MRI scan with contrast dye
- Your blood counts, liver, and kidney function are within acceptable levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (NK cells) for patients with malignant brain tumors that have come back or worsened despite previous treatment. The goal is to see if these specially prepared immune cells can help fight the cancer.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This trial tests a new type of immune therapy using special T cells (a kind of white blood cell) given directly into the brain tumor area. It's for patients with a severe brain tumor that hasn't improved with standard treatments.
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.